<div id="readability-page-1"><p>Chesley Taft &amp; Associates LLC lowered its stake in  Zoetis Inc. (NYSE:ZTS - Free Report) by 61.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,864 shares of the company's stock after selling 63,356 shares during the quarter. Chesley Taft &amp; Associates LLC's holdings in Zoetis were worth $5,833,000 at the end of the most recent quarter.</p><ul><li>Which Pet Stock Should Get Your Tail Wagging in 2024?</li></ul><p>A number of other institutional investors have also made changes to their positions in the stock. Savvy Advisors Inc. grew its position in  Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company's stock valued at $495,000 after acquiring an additional 1,114 shares in the last quarter.  Sound Income Strategies LLC grew its holdings in shares of  Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company's stock valued at $67,000 after purchasing an additional 152 shares in the last quarter.  Canoe Financial LP increased its stake in  Zoetis by 859.0% during the 2nd quarter. Canoe Financial LP now owns 13,369 shares of the company's stock worth $2,085,000 after buying an additional 11,975 shares during the period.  Strs Ohio acquired a new stake in  Zoetis during the 1st quarter worth approximately $22,891,000.  Finally, Chicago Partners Investment Group LLC boosted its position in  Zoetis by 67.0% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company's stock valued at $750,000 after buying an additional 1,961 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Zoetis Price Performance</h2><p>Shares of NYSE ZTS opened at $122.42 on Thursday. The stock's 50-day simple moving average is $129.65 and its 200-day simple moving average is $145.14. The firm has a market capitalization of $53.95 billion, a PE ratio of 20.61, a price-to-earnings-growth ratio of 2.78 and a beta of 0.97. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. </p><ul><li>MarketBeat Week in Review – 07/31 - 08/04</li></ul><p>Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the prior year, the firm posted $1.58 earnings per share. The firm's revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.  As a group, equities research analysts forecast that  Zoetis Inc. will post 6.07 EPS for the current fiscal year. </p><h2>Zoetis Increases Dividend</h2><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. This is an increase from Zoetis's previous quarterly dividend of $0.50. Zoetis's dividend payout ratio (DPR) is 33.67%. </p><h2>Analysts Set New Price Targets</h2><ul><li>Rising Dividend Make Zoetis a Doggone Winner</li></ul><p>Several brokerages have recently issued reports on ZTS. Morgan Stanley reduced their price objective on Zoetis from $211.00 to $175.00 and set an &#34;overweight&#34; rating on the stock in a research note on Monday, November 10th. Stifel Nicolaus reduced their price target on Zoetis from $140.00 to $130.00 and set a &#34;hold&#34; rating on the stock in a research report on Tuesday, November 18th. JPMorgan Chase &amp; Co. lowered their price objective on Zoetis from $230.00 to $200.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, November 5th. HSBC  set a $140.00 target price on shares of Zoetis in a report on Wednesday, December 10th. Finally, KeyCorp started coverage on shares of Zoetis in a report on Thursday, November 20th. They set a &#34;sector weight&#34; rating for the company. Six research analysts have rated the stock with a Buy rating and eight have assigned  a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus price target of $161.55.</p><p><b>View Our Latest Research Report on ZTS</b></p><h2>Zoetis Company Profile</h2> (Free Report)<p>Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Zoetis</li><li>Dividend Payout Ratio Calculator</li><li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li><li>Why is the Ex-Dividend Date Significant to Investors?</li><li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li><li>What is the Australian Securities Exchange (ASX) </li><li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li></ul><p><strong>Want to see what other hedge funds are holding ZTS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zoetis Right Now?</h2><p>Before you consider Zoetis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.</p><p>While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Chesley Taft & Associates LLC reduced its stake in Zoetis Inc. by 61.4% in Q3. Zoetis shares opened at $122.42, with a 52-week range of $115.25-$177.40. Analysts have issued mixed ratings, with a consensus price target of $161.55. Zoetis reported Q3 EPS of $1.70, beating estimates, and increased its dividend to $0.53 per share.</p>

Chesley Taft & Associates LLC Trims Stock Holdings in Zoetis Inc. $ZTS